RxDoctor Payments Data

Jeffrey Johnson, PA

Medical · Port Saint Lucie, FLNPI 1225087687

Payments from drug & device makers

$11,818in general payments, 2019–2025

Across 526 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • UCB, Inc.$1K
  • Lilly USA, LLC$564
  • Incyte Corporation$543
  • plus $3K from 17 others

What the payments were for

  • Food & beverage$11,01393%
  • Education$8047%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,818 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$337,702
Medicare patients
1,418
Services billed
6,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab28$378,099
Skyrizi PenRisankizumab-Rzaa11$229,474
Dupixent PenDupilumab50$214,874
Dupixent SyringeDupilumab25$125,214
OpzeluraRuxolitinib Phosphate11$22,422
Betamethasone Dipropionate219$7,318
Triamcinolone Acetonide544$5,781
Ciclopirox83$3,161
Metronidazole42$2,901
Ketoconazole122$2,086
Clobetasol Propionate55$2,064
Minocycline Hcl62$1,956
Doxycycline Hyclate98$1,932
Ammonium Lactate58$1,378
Fluorouracil20$1,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,849$378,09928 claims
Incyte CorporationOpzelura$543$22,42211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Port Saint Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →